At the same time, based on the research we did to explore the connection between SLC24A3 and tumor-infiltrating immune cells and immune-related gene sets, we found that SLC24A3 can affect the tumor-immune microenvironment, which indicates that SLC24A3 may control the body's pain response by immunomodulation. This evidence concerns the gene SLC24A3 and neoplasm.